◀ Back to MAPK3
MAPK1 — MAPK3
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
MAPK1
→
Complex of HSF1-MAPK3
(increases, HSF1/MAPK3 Activity)
Wang et al., J Biol Chem 2004*
Evidence: We have found that the two pathways interact directly and that heat shock causes the physical association of ERK1 with HSF1, an interaction that promotes the kinase activity of ERK in heat-shocked cells.
-
BioCarta il-2 receptor beta chain in t cell activation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta trefoil factors initiate mucosal healing:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta phosphorylation of mek1 by cdk5/p35 down regulates the map kinase pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta mcalpain and friends in cell motility:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
RAF1
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK2 (MAPK1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta mcalpain and friends in cell motility:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta stat3 signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta phosphorylation of mek1 by cdk5/p35 down regulates the map kinase pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta human cytomegalovirus and map kinase pathways:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta il-2 receptor beta chain in t cell activation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(transcription, activates)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
dynamin gtpase (DNM1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
dynamin gtpase (DNM1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, activates)
-
BioCarta role of egf receptor transactivation by gpcrs in cardiac hypertrophy:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta ccr3 signaling in eosinophils:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta how progesterone initiates the oocyte maturation:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, activates)
-
BioCarta how progesterone initiates the oocyte maturation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta fc epsilon receptor i signaling in mast cells:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta keratinocyte differentiation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta il-2 receptor beta chain in t cell activation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta keratinocyte differentiation:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, inhibits)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta role of egf receptor transactivation by gpcrs in cardiac hypertrophy:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta phospholipids as signalling intermediaries:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(cell proliferation, activates)
-
BioCarta phospholipids as signalling intermediaries:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(cell survival, activates)
-
BioCarta role of erbb2 in signal transduction and oncology:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(translocation, collaborate)
-
BioCarta role of erbb2 in signal transduction and oncology:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta human cytomegalovirus and map kinase pathways:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta human cytomegalovirus and map kinase pathways:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(viral genome replication, collaborate)
-
BioCarta melanocyte development and pigmentation pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta role of erbb2 in signal transduction and oncology:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta trefoil factors initiate mucosal healing:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta human cytomegalovirus and map kinase pathways:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, activates)
-
BioCarta agrin in postsynaptic differentiation:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta erk1/erk2 mapk signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta ccr3 signaling in eosinophils:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta regulation of splicing through sam68:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, activates)
-
BioCarta fc epsilon receptor i signaling in mast cells:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, activates)
-
NCI Pathway Database Fc-epsilon receptor I signaling in mast cells:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
NCI Pathway Database Trk receptor signaling mediated by the MAPK pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
York et al., Nature 1998*
Evidence: mutant phenotype, reporter gene, other species
-
NCI Pathway Database Fc-epsilon receptor I signaling in mast cells:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, activates)
-
NCI Pathway Database S1P1 pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Van Brocklyn et al., Cancer Lett 2002
Evidence: mutant phenotype, assay
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2-active (MAPK3/MAPK1)
→
Erk1-2 (MAPK3/MAPK1)
(modification, collaborate)
Kim et al., Biochemistry 2003*, Amit et al., Nat Genet 2007, Muda et al., J Biol Chem 1996*, Muda et al., J Biol Chem 1996*, Camps et al., Science 1998*
Evidence: assay, physical interaction
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
Erk1-2-active (MAPK3/MAPK1)
→
ERK1-2/ELK1 complex (MAPK3_MAPK1-ELK1)
(modification, collaborate)
Gille et al., EMBO J 1995*, Rao et al., Oncogene 1994*
Evidence: assay, physical interaction
-
NCI Pathway Database mTOR signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Roux et al., Proc Natl Acad Sci U S A 2004, Ma et al., Cell 2005
-
NCI Pathway Database Syndecan-2-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Modrowski et al., J Biol Chem 2000
Evidence: mutant phenotype, assay
-
NCI Pathway Database Integrins in angiogenesis:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay
-
NCI Pathway Database Syndecan-1-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Pakula et al., Glycobiology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database PDGFR-beta signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Taylor et al., Endocrinology 2000, Ory et al., Curr Biol 2003, McKay et al., Proc Natl Acad Sci U S A 2009, Ritt et al., Mol Cell Biol 2010
Evidence: assay, physical interaction
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Bernatchez et al., Br J Pharmacol 2001
Evidence: genetic interaction
-
NCI Pathway Database Integrins in angiogenesis:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Naik et al., J Cell Sci 2006
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Bernatchez et al., Br J Pharmacol 2001, Xia et al., J Clin Invest 1996*, Takahashi et al., Oncogene 1997*
Evidence: mutant phenotype
-
NCI Pathway Database Arf6 downstream pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Tague et al., Proc Natl Acad Sci U S A 2004*, Li et al., Cancer Res 2006*, Tushir et al., EMBO J 2007
Evidence: genetic interaction, assay
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2-active (MAPK3/MAPK1)
→
Erk1-2 (MAPK3/MAPK1)
(modification, collaborate)
Brondello et al., Oncogene 1995*, Sun et al., Science 1994*, Sun et al., Cell 1993*, Shapiro et al., J Biol Chem 1998*
Evidence: assay
-
NCI Pathway Database Regulation of Telomerase:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Kawauchi et al., J Immunol 2005
Evidence: assay, physical interaction
-
NCI Pathway Database Presenilin action in Notch and Wnt signaling:
ERK1 (MAPK3)
→
ERK2 (MAPK1)
(modification, activates)
Chu et al., J Biol Chem 2002*
Evidence: assay
-
NCI Pathway Database Ceramide signaling pathway:
ERK2 (MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
Westwick et al., J Biol Chem 1995*
Evidence: assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Schaeper et al., J Cell Biol 2000, Maroun et al., Mol Cell Biol 2000
Evidence: mutant phenotype
-
NCI Pathway Database CXCR3-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Bonacchi et al., J Biol Chem 2001, Smit et al., Blood 2003
Evidence: assay
-
NCI Pathway Database Netrin-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Forcet et al., Nature 2002, Hérincs et al., J Cell Sci 2005
Evidence: genetic interaction, mutant phenotype
-
NCI Pathway Database Neurotrophic factor-mediated Trk receptor signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Yamashita et al., J Biol Chem 1999
Evidence: mutant phenotype, assay, other species
-
NCI Pathway Database Signaling events regulated by Ret tyrosine kinase:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Uchida et al., J Cell Sci 2006
-
NCI Pathway Database IL2-mediated signaling events:
Erk1-2-active (MAPK3/MAPK1)
→
IL2/IL2R alpha/beta/gamma/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/ERK1-2 complex (IL2RA-IL2RB-IL2RG-IL2-JAK1-LCK-JAK3-SHC1-GRB2-SOS1-GAB2-MAPK3_MAPK1)
(modification, collaborate)
Gadina et al., J Biol Chem 2000, Arnaud et al., Biochem J 2004, Arnaud et al., J Immunol 2004, Gadina et al., J Immunol 1998, Gadina et al., J Immunol 1999
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database Nongenotropic Androgen signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Estrada et al., Endocrinology 2003*
Evidence: mutant phenotype, assay, other species
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Schaeper et al., J Cell Biol 2000, Maroun et al., Mol Cell Biol 2000
Evidence: mutant phenotype
-
NCI Pathway Database ErbB4 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Vaskovsky et al., J Neurochem 2000, Ma et al., J Neurosci 2003
Evidence: mutant phenotype
-
NCI Pathway Database IL2-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Perkins et al., J Exp Med 1993*
Evidence: mutant phenotype, other species
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Catalanotti et al., Nature structural & molecular biology 2009
Evidence: assay
-
NCI Pathway Database VEGFR3 signaling in lymphatic endothelium:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Mäkinen et al., EMBO J 2001
Evidence: assay
-
NCI Pathway Database TRAIL signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Tran et al., J Biol Chem 2001, Secchiero et al., Circulation 2003*
Evidence: mutant phenotype, assay
-
NCI Pathway Database S1P4 pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Van Brocklyn et al., J Biol Chem 1999
Evidence: mutant phenotype, assay
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Crews et al., Proc Natl Acad Sci U S A 1992*
Evidence: assay, other species
-
NCI Pathway Database Integrins in angiogenesis:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Naik et al., Blood 2003, Eliceiri et al., J Cell Biol 1998
Evidence: mutant phenotype, assay, other species
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2-active (MAPK3/MAPK1)
→
Erk1-2 (MAPK3/MAPK1)
(modification, collaborate)
Saxena et al., J Biol Chem 1999*
Evidence: assay
-
NCI Pathway Database Angiopoietin receptor Tie2-mediated signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Harfouche et al., FASEB J 2003*, Yoon et al., Biochem Biophys Res Commun 2003*, Harfouche et al., FASEB J 2005
Evidence: mutant phenotype, assay
-
NCI Pathway Database FGF signaling pathway:
Erk1-2-active (MAPK3/MAPK1)
→
Erk1-2 (MAPK3/MAPK1)
(modification, collaborate)
Zhao et al., J Biol Chem 2001, Xiao et al., J Biol Chem 2002, Bryant et al., Mol Biol Cell 2005, Matsui et al., Circ Res 2011, Elfenbein et al., Science signaling 2012
Evidence: mutant phenotype, assay
-
NCI Pathway Database VEGFR1 specific signals:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Bernatchez et al., Br J Pharmacol 2001, Meyer et al., J Biol Chem 2003*
Evidence: assay, other species
-
NCI Pathway Database BCR signaling pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
-
NCI Pathway Database ErbB2/ErbB3 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Monje et al., J Biol Chem 2008, Vijapurkar et al., J Biol Chem 1998
Evidence: assay
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2-active (MAPK3/MAPK1)
→
ERK1-2/ELK1 complex (MAPK3_MAPK1-ELK1)
(modification, collaborate)
Gille et al., EMBO J 1995*, Rao et al., Oncogene 1994*
Evidence: assay, physical interaction
-
NCI Pathway Database S1P3 pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Baudhuin et al., FASEB J 2004
Evidence: mutant phenotype, assay
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Barouch-Bentov et al., J Immunol 2005
Evidence: mutant phenotype, other species
-
NCI Pathway Database VEGFR3 signaling in lymphatic endothelium:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Salameh et al., Blood 2005
Evidence: assay
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Glading et al., J Biol Chem 2001*, Howe et al., Cell 1992, Roy et al., Mol Cell Biol 2005, Ren et al., Proc Natl Acad Sci U S A 2007, Minden et al., Science 1994, Zheng et al., J Biol Chem 1993, Huang et al., Proc Natl Acad Sci U S A 1993
Evidence: assay, physical interaction
-
NCI Pathway Database Cellular roles of Anthrax toxin:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Vitale et al., Biochem Biophys Res Commun 1998*
Evidence: assay
-
NCI Pathway Database Signaling events mediated by VEGFR1 and VEGFR2:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Takahashi et al., Oncogene 1999*, Xia et al., J Clin Invest 1996*
Evidence: mutant phenotype
-
NCI Pathway Database EPHB forward signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Vindis et al., J Cell Biol 2003
Evidence: mutant phenotype
-
NCI Pathway Database S1P2 pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
An et al., J Biol Chem 2000, Arikawa et al., J Biol Chem 2003, Gonda et al., Biochem J 1999
Evidence: mutant phenotype, assay
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Xu et al., J Biol Chem 1999*, Howe et al., Cell 1992, McKay et al., Proc Natl Acad Sci U S A 2009, Minden et al., Science 1994, Zheng et al., J Biol Chem 1993, Huang et al., Proc Natl Acad Sci U S A 1993
Evidence: assay, physical interaction
-
NCI Pathway Database Downstream signaling in naïve CD8+ T cells:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Crews et al., Proc Natl Acad Sci U S A 1992*
Evidence: assay, other species
-
NCI Pathway Database Ras signaling in the CD4+ TCR pathway:
Erk1-2-active (MAPK3/MAPK1)
→
Erk1-2 (MAPK3/MAPK1)
(modification, collaborate)
Saxena et al., J Biol Chem 1999*
Evidence: assay
-
NCI Pathway Database IFN-gamma pathway:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Hu et al., J Biol Chem 2001, Roy et al., Proc Natl Acad Sci U S A 2002
Evidence: mutant phenotype
-
NCI Pathway Database GMCSF-mediated signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Guthridge et al., Blood 2004, Lanfrancone et al., Oncogene 1995, Sato et al., EMBO J 1993, Itoh et al., Mol Cell Biol 1998*, Jenkins et al., Blood 1998*
Evidence: genetic interaction
-
NCI Pathway Database ErbB1 downstream signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Catalanotti et al., Nature structural & molecular biology 2009, McKay et al., Proc Natl Acad Sci U S A 2009
Evidence: assay
-
NCI Pathway Database Endothelins:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Yogi et al., Arterioscler Thromb Vasc Biol 2007
-
NCI Pathway Database CDC42 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Koh et al., J Cell Sci 2008, Koh et al., J Cell Sci 2009
Evidence: mutant phenotype
-
NCI Pathway Database Nongenotropic Androgen signaling:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Unni et al., Cancer Res 2004, Cheng et al., Endocrinology 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by PRL:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
-
NCI Pathway Database ALK1 signaling events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Lee et al., J Biol Chem 2007
Evidence: mutant phenotype, assay
-
NCI Pathway Database Osteopontin-mediated events:
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Rangaswami et al., Glycoconj J 2006
Evidence: mutant phenotype, assay
-
NCI Pathway Database Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met):
Erk1-2 (MAPK3/MAPK1)
→
Erk1-2-active (MAPK3/MAPK1)
(modification, collaborate)
Karihaloo et al., J Biol Chem 2001*, Paumelle et al., Oncogene 2002
Evidence: assay
-
Reactome Reaction:
MAPK1
→
MAPK3
(reaction)
Yang et al., J Biol Chem 2003*, Xiong et al., J Biol Chem 2003*, Preger et al., Proc Natl Acad Sci U S A 2004*, Ziv et al., J Biol Chem 2006*, Zheng et al., J Biol Chem 1993*
-
WikiPathways Hypothesized Pathways in Pathogenesis of Cardiovascular Disease:
Complex of ANGPT2-AGTR1
→
Complex of MAPK3-MAPK8-MAPK1-MAPK14
(activation)
-
WikiPathways Hypothesized Pathways in Pathogenesis of Cardiovascular Disease:
SHC1
→
Complex of MAPK3-MAPK8-MAPK1-MAPK14
(activation)
-
WikiPathways 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression:
Complex of MAP2K2-MAP2K1
→
Complex of MAPK1-MAPK3
(activation)
-
WikiPathways 4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression:
EIF4EBP1
→
Complex of MAPK1-MAPK3
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Hprd Interaction:
Complex of 26 proteins
(in vivo)
Tohgo et al., J Biol Chem 2003
-
IRef Innatedb Interaction:
Complex of INSR-MAPK1-MAPK3
(unknown, -)
Lin et al., Mol Cell Biol Res Commun 2000*
-
IRef Innatedb Interaction:
Complex of MAPK3-C1QBP-MAPK1
(unknown, -)
Majumdar et al., Biochem Biophys Res Commun 2002*
-
IRef Innatedb Interaction:
Complex of KSR2-MAPK1-MAPK3
(unknown, -)
Channavajhala et al., J Biol Chem 2003*
-
IRef Innatedb Interaction:
Complex of MAPK3-ADAM17-MAPK1
(unknown, -)
Díaz-Rodríguez et al., Mol Biol Cell 2002*
-
IRef Intact Interaction:
Complex of MAPK3-CD24-LYN-CD24-MAPK1-MAPK3-MAPK1-LYN
(association, anti bait coimmunoprecipitation)
Su et al., Molecular cancer 2012*
-
IRef Intact Interaction:
Complex of MAPK12-PDCD6IP-HMGB1-NAV1-CEP350-RPS6KA2-MAPK3-RPS6KA3-MAPK1
(association, tandem affinity purification)
Varjosalo et al., Cell reports 2013
-
IRef Intact Interaction:
Complex of MAPK1-PHF3-MAPK3-DHPS-RPS6KA2-TEK
(association, tandem affinity purification)
Varjosalo et al., Cell reports 2013
-
IRef Intact Interaction:
MAPK3
—
MAPK1
(physical association, proximity ligation assay)
Liu et al., Mol Cell Proteomics 2013
-
IRef Intact Interaction:
Complex of RAF1-MAPK1-MAPK3-MDM2
(association, anti tag coimmunoprecipitation)
Beaulieu et al., Cell 2008*
Text-mined interactions from Literome
Lopaczynski et al., Horm Metab Res 1999
(Osteosarcoma) :
Extracellular signal regulated kinase 1 appeared to be activated in resting cells and addition of insulin-like growth factor I
resulted in the activation primarily of
extracellular signal regulated kinase 2
Schechter et al., Neurosci Lett 1999
:
Insulin inhibited the phosphorylation of the insulin receptor and IRS-1 and decreased the activity of the
ERK-1 , and
inhibited the activation of the
ERK-2
Khan et al., J Biol Chem 2000
:
These data demonstrate that incubation of macrophages with alpha1 : SRARKQAASIKVAVSADR, but not intact laminin-1, triggers protein kinase C-dependent
activation of
MAPK (
erk1/2 ), leading to the up-regulation of proteinase expression ... These data demonstrate that incubation of macrophages with alpha1 : SRARKQAASIKVAVSADR, but not intact laminin-1, triggers protein kinase C-dependent
activation of
MAPK (
erk1/2 ), leading to the up-regulation of proteinase expression
Raggatt et al., J Endocrinol 2000
:
CT treatment of cells expressing the insert -ve, but not insert +ve hCTR,
induced the phosphorylation of Erk1/2
MAPK , which persisted for at least 72 h. Treatment of cells expressing the insert -ve hCTR with the MAPK kinase ( MEK ) inhibitor, PD-98059, inhibited the phosphorylation of
Erk1/2 and abrogated the growth inhibitory effects of salmon CT, the accumulation of cells in G2, and the associated induction of p21 ( WAF1/CIP1 ) ... CT treatment of cells expressing the insert -ve, but not insert +ve hCTR,
induced the phosphorylation of Erk1/2
MAPK , which persisted for at least 72 h. Treatment of cells expressing the insert -ve hCTR with the MAPK kinase ( MEK ) inhibitor, PD-98059, inhibited the phosphorylation of
Erk1/2 and abrogated the growth inhibitory effects of salmon CT, the accumulation of cells in G2, and the associated induction of p21 ( WAF1/CIP1 )
Conejo et al., J Cell Physiol 2001
(MAP Kinase Signaling System) :
This mitogenic effect of insulin was precluded by inhibition of p70S6-kinase ( either by rapamycin or by the PI3-kinase inhibitor LY294002 ) as well as by inhibition of
p44/p42-MAPK with PD098059, but was not
affected by inhibition of
p38-MAPK
Rosengart et al., Shock 2002
:
Moreover, CD pretreatment abrogated adherence induced activation of Pyk2, a major focal adhesion kinase, and
ERK 1/2 , a component of the mitogen activated protein kinase ( MAPK ) signaling pathway, and it completely
inhibited LPS induced
ERK 1/2 activation
Blaschke et al., Biochem Biophys Res Commun 2002
(Anoxia) :
Hypoxia induced a time dependent activation of
ERK 1/2 and p38
MAPK activation in human VSMCs, which were completely abolished by PD98059 or SB203580, respectively ... Hypoxia induced a time dependent activation of
ERK 1/2 and p38
MAPK activation in human VSMCs, which were completely abolished by PD98059 or SB203580, respectively
Wang et al., Invest Ophthalmol Vis Sci 2003
(MAP Kinase Signaling System) :
Western blot analysis showed that both wounding and application of an EF enhanced the activation of
ERK 1/2 independently and that U0126 completely
inhibited these activations of
ERK 1/2 in monolayers
Choi et al., Infect Immun 2003
:
Thus, we examined whether H. pylori induced
extracellular signal regulated kinase 1 and 2 ( ERK1/2 ) and p38
MAPK activation
affects gastric epithelial cell apoptosis and bcl-2 family gene expression, especially in relation to the cagA status of an H. pylori strain
Sawamura et al., J Neurochem 2003
(Niemann-Pick Diseases) :
In CT43 cells, mitogen activated protein ( MAP ) kinase
Erk1/2 was activated and the specific
MAPK inhibitor, PD98059,
attenuated the hyperphosphorylation of tau ... In CT43 cells, mitogen activated protein ( MAP ) kinase
Erk1/2 was activated and the specific
MAPK inhibitor, PD98059,
attenuated the hyperphosphorylation of tau
Pippin et al., J Clin Invest 2003
:
Sublytic C5b-9 increased
extracellular signal regulated kinase-1 and -2 ( ERK-1 and -2 ), and inhibiting
ERK-1 and -2 reduced the increase in p21 and GADD45 and augmented the DNA damage response to sublytic C5b-9 induced injury
Frank et al., J Biol Chem 2003
:
The inhibitory effect of TGF-beta1 on sodium uptake and alphaENaC expression in ATII cells was
mediated by activation of the
MAPK ,
ERK1/2
Kotturi et al., J Biol Chem 2003
:
We found that treatment of T lymphocytes with ( +/- ) Bay K 8644 increased intracellular Ca2+ and
induced the activation of phosphoextracellular regulated kinase 1/2 (
Erk1/2 ), whereas nifedipine blocked Ca2+ influx, the activity of
Erk1/2 and nuclear factor of activated T cells ( NFAT ), interleukin-2 (IL-2) production, and IL-2 receptor expression
Sorensen et al., Mol Pharmacol 2003
:
Comparison of the intracellular signaling pathways of glial PAR-1, LPA, and S1P receptors indicates that each receptor class activates multiple downstream signaling pathways, including Gq/11 directed inositol lipid/Ca2+ signaling, Gi/o
activation of mitogen activated protein kinases (
MAPK ) (
extracellular signal regulated kinase 1/2 and stress activated protein kinase/c-jun N-terminal kinase, but not p38 ), and activation of Rho pathways
Cantó et al., J Biol Chem 2004
:
HRG also stimulated the activity of p70S6K,
p38MAPK , and p42/p44MAPK and inhibition of
p42/p44MAPK partially
repressed HRG action on glucose uptake
Mathur et al., Nat Med 2004
(MAP Kinase Signaling System) :
ERK-1/2 inhibition or IL-10 neutralization
restores CD40 induced
p38MAPK activation and parasite killing in macrophages and the BALB/c mouse, a susceptible host ...
ERK-1/2 inhibition or IL-10 neutralization
restores CD40 induced
p38MAPK activation and parasite killing in macrophages and the BALB/c mouse, a susceptible host
Couty et al., Biol Cell 2004
(Disease Models, Animal...) :
In in vitro systems, HHV-8-GPCR signals via multiple transduction pathways including, activation of phospholipase C and PKC, inhibition of adenylyl cyclase, activation of nuclear factor-kappaB ; activation PI 3-kinase,
p42/44 MAPK and Akt/PKB, and
activation of JNK/SAPK, p38
MAPK and RAFTK
Fujii et al., Biochem Biophys Res Commun 2004
(Carcinoma, Hepatocellular...) :
CCL20 stimulated growth of HuH7 cells was abrogated by the inhibition of downstream signal transduction pathway
mediated by
p44/42 MAPK , but not by p38
MAPK or SAPK/JNK
Hers et al., Biochem J 2005
:
The effect of insulin on phosphorylation of both these sites required the activation of PI3K and the MAPKs ( mitogen activated protein kinases ) ERK1/2 (
extracellular-signal regulated kinase 1 and 2 ), but not the
activation of mTOR ( mammalian target of rapamycin ) /p70S6 kinase, JNK ( c-Jun N-terminal kinase ) or
p38MAPK
Jiang et al., J Mol Neurosci 2005
(MAP Kinase Signaling System) :
A selective
MAPK kinase inhibitor, U0126,
blocked the H2O2 induced phosphorylation of
Erk1/2 ( extracellular signal regulated kinase ) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment ... A selective
MAPK kinase inhibitor, U0126,
blocked the H2O2 induced phosphorylation of
Erk1/2 ( extracellular signal regulated kinase ) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment
Hughes-Fulford et al., Cell Signal 2005
:
Extracellular signal regulated kinase-2 ( ERK2 ) pathway was found to be significantly activated greater than seven-fold within 30 min ; however, there was little activation of
ERK-1 and no
activation of JNK or p38
MAPK
Shin et al., Biol Pharm Bull 2005
:
We show that among the
mitogen activated protein kinase family
activation of phosphorylation of
extra cellular signal regulated kinase 1/2 ( ERK1/2, p44/42 ) and p38, but not c-jun NH2-terminal kinase is inhibited
Jacquel et al., Oncogene 2006
(Leukemia) :
Differentiation of K562 cells by the combination of PMA and SB
required Erk1/2 activation, a threshold of JNK activation and p38
MAPK inhibition ... Differentiation of K562 cells by the combination of PMA and SB
required Erk1/2 activation, a threshold of JNK activation and p38
MAPK inhibition
Ohkawara et al., Eur J Pharmacol 2005
:
Astrapterocarpan
inhibited PDGF-BB induced phosphorylation of
extracellular signal regulated kinase 1/2 ( ERIC1/2 )
mitogen activated protein ( MAP ) kinase
Opperman et al., Dev Dyn 2006
:
In summary, Tgf-beta2 stimulated Erk1/2 phosphorylation and
induced Egf and
Erk1/2 expression, associated with suture closure after 72 hr. Blocking
Erk1/2 activity with PD inhibited these effects but increased Smad2/3 expression
Eitenmüller et al., Circ Res 2006
(Arterial Occlusive Diseases) :
The activities of Ras and
ERK-1 , -2 were markedly increased in collateral vessels of the shunt experiment, and infusions of L-NAME and L-NNA strongly
inhibited MAPK activity as well as shunt induced arteriogenesis
Romano et al., Endocrinology 2006
:
In the present study, we focused on the involvement of the phosphoinositide 3-kinase (PI3K)/Akt pathway in the
MAPK ERK-1/2 regulation and PRL secretion in pituitary cells ... In the present study, we focused on the involvement of the phosphoinositide 3-kinase (PI3K)/Akt pathway in the
MAPK ERK-1/2 regulation and PRL secretion in pituitary cells
Rahman et al., J Immunol 2006
(Asthma...) :
IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells :
role of
MAPK (
Erk1/2 , JNK, and p38 ) pathways ... IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells :
role of
MAPK (
Erk1/2 , JNK, and p38 ) pathways
Koch et al., Respir Med 2007
(Asthma) :
In conclusion, ( 1 ) p38MAPK-pathway rather than ERK-pathway may play a more basic role in the regulation of the increased T-bet expression in asthma, and ( 2 ) ERK- and
p38MAPK-activation modulate IFNgamma expression independently of T-bet and this regulatory role of
ERK-1/-2 on IFNgamma release is
impaired in asthma ... In conclusion, ( 1 ) p38MAPK-pathway rather than ERK-pathway may play a more basic role in the regulation of the increased T-bet expression in asthma, and ( 2 ) ERK- and
p38MAPK-activation modulate IFNgamma expression independently of T-bet and this regulatory role of
ERK-1/-2 on IFNgamma release is
impaired in asthma
Yano et al., Circ Res 2007
(Inflammation) :
Statins activate peroxisome proliferator activated receptor gamma through
extracellular signal regulated kinase 1/2 and p38
mitogen activated protein kinase dependent cyclooxygenase-2 expression in macrophages
Suzuki et al., J Cell Physiol 2008
(Hemorrhage) :
Two hrs thereafter, Kupffer cells and SMPhi production of IL-6, TNF-alpha, and IL-10,
activation of
MAPK ( p38,
ERK-1/2 , and JNK ), and transcription factors ( NF-kappaB and AP-1 ) were determined ... Two hrs thereafter, Kupffer cells and SMPhi production of IL-6, TNF-alpha, and IL-10,
activation of
MAPK ( p38,
ERK-1/2 , and JNK ), and transcription factors ( NF-kappaB and AP-1 ) were determined
Hasan et al., Circ Res 2008
:
Inhibiting hemin induced
ERK-1/2 activation by U0126 (
MAPK-inhibitor ), the antioxidant N-acetyl cysteine, the NADPH oxidase inhibitors apocynin and diphenyleneiodonium chloride, the superoxide scavenger tiron, or tricarbonyldichlororuthenium ( II ) -dimer ( carbon-monoxide donor ; CORM-2 ) blocked hemin induced Egr-1 expression ... Inhibiting hemin induced
ERK-1/2 activation by U0126 (
MAPK-inhibitor ), the antioxidant N-acetyl cysteine, the NADPH oxidase inhibitors apocynin and diphenyleneiodonium chloride, the superoxide scavenger tiron, or tricarbonyldichlororuthenium ( II ) -dimer ( carbon-monoxide donor ; CORM-2 ) blocked hemin induced Egr-1 expression
Rivas et al., Exp Cell Res 2008
(Carcinoma, Ductal, Breast...) :
A TNF alpha-specific mutein selectively binding to TNFR1
induced p42/p44 MAPK , JNK, Akt activation, NF-kappa B transcriptional activation and cell proliferation, just like wild-type TNF alpha, while a mutein selective for TNFR2 induced only p42/p44
MAPK activation
Suzuki et al., Cytokine 2008
(Hemorrhage...) :
Two hours thereafter, T cell production of IL-2 and IFN-gamma and
activation of
MAPK ( p38,
ERK-1/2 and JNK ) were determined ... Two hours thereafter, T cell production of IL-2 and IFN-gamma and
activation of
MAPK ( p38,
ERK-1/2 and JNK ) were determined
Matsubayashi et al., J Pathol 2008
(Breast Neoplasms...) :
In addition, GRK4-over expressing cells activated the
mitogen activated protein kinase ( MAPK )
mediated by
ERK 1/2 and JNK phosphorylation in breast cancer derived cell lines ... In addition, GRK4-over expressing cells activated the mitogen activated protein kinase (
MAPK )
mediated by
ERK 1/2 and JNK phosphorylation in breast cancer derived cell lines
Chandra et al., Clin Exp Immunol 2008
(Leishmaniasis, Visceral...) :
Parasites also modulated the TLR2
stimulated mitogen activated protein kinase ( MAPK ) pathway by suppressing MAPK P(38) phosphorylation and activating extracellular regulated kinase
(ERK)1/2 phosphorylation ... Parasites also modulated the TLR2
stimulated mitogen activated protein kinase ( MAPK ) pathway by suppressing MAPK P(38) phosphorylation and activating extracellular regulated kinase
(ERK)1/2 phosphorylation
Salamat et al., Dev Comp Immunol 2009
:
These results suggest that PKC induced
activation of the
mitogen activated protein kinase ,
ERK1/2 , is involved in cell division in the APO
Sheng et al., J Neuroimmune Pharmacol 2009
(MAP Kinase Signaling System) :
IL-1beta triggered the activation of p38 and ERK1/2 (
p44/42) MAP kinase (MAPK) signaling pathways, but WIN55,212-2 mainly
inhibited p38
MAPK phosphorylation
Kozono et al., Biochem Biophys Res Commun 2010
:
CP55940 ( CB1/CB2 agonist ) induced phosphorylation of the extracellular regulated kinases
(ERK) 1/2 , p38 mitogen activated protein kinase ( p38MAPK ), and Akt in HGFs. Wound closure by CP55940 in an in-vitro scratch assay was significantly
suppressed by inhibitors of MAP kinase kinase ( MEK ),
p38MAPK , and phosphoinositol 3-kinase (PI3-K) ... CP55940 ( CB1/CB2 agonist ) induced phosphorylation of the extracellular regulated kinases
(ERK) 1/2 , p38 mitogen activated protein kinase ( p38MAPK ), and Akt in HGFs. Wound closure by CP55940 in an in-vitro scratch assay was significantly
suppressed by inhibitors of MAP kinase kinase ( MEK ),
p38MAPK , and phosphoinositol 3-kinase (PI3-K)
McClelland et al., Proc Natl Acad Sci U S A 2010
(MAP Kinase Signaling System) :
RNA interference and biochemical experiments support the model that ephrin-B3 regulates synapse density by directly binding to
Erk1/2 to
inhibit postsynaptic
Ras/mitogen activated protein kinase signaling ... RNA interference and biochemical experiments support the model that ephrin-B3 regulates synapse density by directly binding to
Erk1/2 to
inhibit postsynaptic
Ras/mitogen activated protein kinase signaling
Krug et al., Hypertension 2010
:
MR blockade and
extracellular signal regulated kinase 1/2 mitogen activated protein kinase inhibition prevent age associated increases of transforming growth factor-beta, intercellular adhesion molecule 1, and procollagen 1
Bocelli-Tyndall et al., Arthritis Rheum 2010
:
Both
MAPK/ERK-1/2 and phosphatidylinositol 3-kinase/Akt controlled cell proliferation and HLA-DR expression, but only
MAPK/ERK-1/2 controlled the induction of the class II MHC transcription activator protein CIITA, the major determinant of HLA-DR transcription ... Both
MAPK/ERK-1/2 and phosphatidylinositol 3-kinase/Akt controlled cell proliferation and HLA-DR expression, but only
MAPK/ERK-1/2 controlled the induction of the class II MHC transcription activator protein CIITA, the major determinant of HLA-DR transcription ... Both
MAPK/ERK-1/2 and phosphatidylinositol 3-kinase/Akt controlled cell proliferation and HLA-DR expression, but only
MAPK/ERK-1/2 controlled the induction of the class II MHC transcription activator protein CIITA, the major determinant of HLA-DR transcription
Jeong et al., J Pharm Pharmacol 2011
(MAP Kinase Signaling System) :
Additionally, PD-98058 ( 10 µm ), a selective
ERK 1/2 MAPK inhibitor, and SB-203580 ( 10 µm ), a selective p38
MAPK inhibitor , significantly reduced the MIGB induced contraction of ileal longitudinal muscles ... Additionally, PD-98058 ( 10 µm ), a selective
ERK 1/2 MAPK inhibitor, and SB-203580 ( 10 µm ), a selective p38
MAPK inhibitor , significantly reduced the MIGB induced contraction of ileal longitudinal muscles
Li et al., Sheng Li Xue Bao 2011
(MAP Kinase Signaling System) :
The results showed U0126
prevented the activation of
Erk1/2 maintained by GRP75, but the total
Erk1/2 expression was not affected
Boomsma et al., PloS one 2012
:
ERK 1/2 phosphorylation was reduced in CM treated H9c2 cells, and inhibition of
ERK 1/2 reduced the phosphorylation of Akt ( Ser473 ), Akt ( Thr308 ) and Bad ( Ser112 )
Upadhya et al., Development 2013
(Lens Diseases) :
Interestingly, loss of
MAPK1 subsequently
induces upregulation of phosphorylated
MAPK3 ( pMAPK3 ) levels in the lens epithelium ; however, this increase in pMAPK3 is not sufficient to restore cell proliferation in the germinative zone
Siddhanti et al., Endocrinology 1995
:
We found that PMA stimulated DNA synthesis was associated with increments in tyrosine phosphorylation of p44mapk ( ERK1 ) and
p42mapk ( ERK2 ) and
activation of Raf-1, MKK, and
MAPK in these cells ... We found that PMA stimulated DNA synthesis was associated with increments in tyrosine phosphorylation of
p44mapk ( ERK1 ) and p42mapk ( ERK2 ) and
activation of Raf-1, MKK, and
MAPK in these cells ... FSK treatment of osteoblasts, which raised intracellular cAMP levels and inhibited DNA synthesis, blocked PKC stimulated tyrosine phosphorylation of p44mapk ( ERK1 ) and
p42mapk ( ERK2 ) as well as
inhibited PKC stimulated
MAPK and Raf-1 activities ... FSK treatment of osteoblasts, which raised intracellular cAMP levels and inhibited DNA synthesis, blocked PKC stimulated tyrosine phosphorylation of
p44mapk ( ERK1 ) and p42mapk ( ERK2 ) as well as
inhibited PKC stimulated
MAPK and Raf-1 activities
Rose et al., J Immunol 1997
:
The selective
MAPK/extracellular signal regulated kinase-1 ( MEK-1 ) inhibitor PD 098059
inhibited activation of
p42MAPK induced by Fc gamma R cross linking, but not p38 or JNK/SAPK activation ... The selective
MAPK/extracellular signal regulated kinase-1 ( MEK-1 ) inhibitor PD 098059
inhibited activation of
p42MAPK induced by Fc gamma R cross linking, but not p38 or JNK/SAPK activation
Pyne et al., Biochem J 1997
:
This occurs via a pathway that involves : ( 1 ) the protein kinase C ( PKC ) -dependent activation of mitogen activated protein kinase (
MAPK); (2 ) the
MAPK dependent phosphorylation and activation of cytosolic phospholipase A2 (cPLA2) and ( 3 ) the utilization of cPLA2 derived arachidonate by the cyclo-oxygenase pathway to produce prostaglandin E2 ( PGE2 )
Kumar et al., J Biol Chem 1998
:
These results show that IL-1beta- or TNF induced LDL receptor expression requires
ERK-1/2 activation, that the p38 (
MAPK ) pathway negatively
regulates LDL receptor expression, and that sterols inhibit induction at a point downstream of ERK-1/2 in HepG2 cells ... These results show that IL-1beta- or TNF induced LDL receptor expression requires
ERK-1/2 activation, that the p38 (
MAPK ) pathway negatively
regulates LDL receptor expression, and that sterols inhibit induction at a point downstream of ERK-1/2 in HepG2 cells
Ainbinder et al., Recept Signal Transduct 1997
(Carcinoma, Hepatocellular...) :
Evidence is presented that stimulation of c-fos transcription by MC involves a signal transduction pathway, which includes
activation of the small G protein Ras, Raf-1 kinase, and the
mitogen activated protein ( MAP ) kinases ,
ERK1 and ERK2
Lundberg et al., J Mol Cell Cardiol 1998
:
Platelet derived growth factor BB ( PDGF BB )
activation of the mitogen activated protein kinases (
MAPK ),
ERK1 and ERK2, has been shown to be necessary for mitogen stimulated proliferation, but its role in regulating cell migration and its relationship to other chemotactic signaling events, such as CamKII activation, has not been defined